HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Dr. Stephen A. Barat Ph.D.

Senior Vice President of Therapeutics

Mr. Byron T. Lawson

Senior Vice President & Chief Commercial Officer

Dr. Christina M. Carruthers Ph.D.

Vice President of Target Strategy & Early Devel.

Dr. Debra A. Gordon

Senior Vice President & Chief Legal Counsel

Dr. Patrick C. Roche

Senior Vice President of R&D

Debrah  Thompson

Vice President of Scientific Innovation

Mr. Shaun D. McMeans

Senior Vice President, Chief Financial Officer, Sec. & Treasurer

Ms. Laura Lee Godlewski

Senior Vice President of Fin. & Admin.

Mr. John L. Lubniewski

Pres, Chief Executive Officer & Director

Diagnostika un pētniecība

HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. Vadības struktūra

Informācija par vadību